IBM drug receives Fast Track designation

Published Date
19/12/2019
Author
Louise Clarke
Category
Research
Orange box stating: Breaking news research

Orphazyme have announced that the U.S Food and Drug Administration (FDA) have granted the drug, arimoclomol, Fast Track designation.

The drug has been developed as a potential treatment for sporadic inclusion body myositis (sIBM). Fast Track designation is designed to expedite the development and review of drugs in the US.

We can expect results from the current phase 2/3 trial in the first half of 2021.

Read the press release from Orphazyme here.

If you have any questions about this report or any other IBM research, please contact the MDUK Research Line on 020 7803 4813 or email research@musculardystrophyuk.org.

Keep in touch